Legend Biotech (LEGN) Reports $1.9B Sales for CARVYKTI in 2025
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowLegend Biotech Corporation (LEGN) announced financial results for 2025, achieving $1.9 billion in net trade sales from its CARVYKTI therapy, including ~$555 million in Q4. The company reported a collaboration revenue increase to $277.6 million in the final quarter. With over 10,000 patients treated and a global footprint expanding to 294 sites across 14 markets, LEGN is positioned for growth. Additionally, the company opened a new 31,000-square-foot R&D facility in Philadelphia to support its pipeline advancements.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Aeromexico Plans New US Flights After Washington Lifts Restrictions
Oct 19
SpaceX AI Computing Power Rental Driving Revenue Growth but Raising Costs
Oct 19
A&W (TSX:AW) Q3 Results Show Margin Squeeze Impact
Oct 18
Aurum PropTech Focuses on Profits and Scale at Earnings Call
Oct 18